Tuesday, December 06, 2016 8:42:27 PM
Subject to the terms and conditions of the Securities Purchase Agreement, the Company, at its option, may issue and sell to GP L, and GPL may purchase from the Company, the Shares upon the Company’s delivery of written notices to GPL and subject to agreement by the parties on pricing. The aggregate maximum amount of all purchases that GPL may make under the Securities Purchase Agreement shall not exceed $5 million. Once a written notice is received by GPL, it shall not be terminated, withdrawn or otherwise revoked by the Company. GPL is not obligated to purchase any Shares unless and until the Company has qualified the Shares pursuant to an offering statement on Form 1-A (or on such other form as is available to the Company), which is required to be effective within six months of the execution of the Agreement.
Additionally, on Dec. 5, 2016, the Company issued to GPL a Convertible Promissory Note (the “Note”) in the principal amount of $50,000 as payment of a commitment fee to induce GPL to enter into the Agreements. The Note accrues interest at the rate of five percent (5%) p er annum and is due in full on or before Dec. 5, 2017. The Note also prohibits prepayment of the principal. GPL has the right to convert all or any portion of the note balance at any time at a conversion price per share of seventy percent (70%) of the lowest Trading Price during the Valuation Period (as defined and calculated pursuant to the Note), which is adjustable in accordance with the Note terms in the event certain capital reorganization, merger, or liquidity events of the Company as further described in the Note.
“We are very excited to have this investment agreement in place as a primary funding vehicle for the company” said Chandana Basu, CEO of PPJ Healthcare Enterprises. ”PPJE plans to use this initial capital for the growth of our pure cannabis-infused edible business, our medical practice management and billing software and other healthcare service-related business.
“This will be key for us and our investors as we expand the busine ss plan for PPJE to account for industry changes as well as the expansion of legalized medicinal and recreational marijuana use.”
As always, PPJE management advises shareholders, company followers and prospective investors to contact their financial advisors if they have questions or concerns about their individual accounts and investment choices. Regarding other news and events, the company reminds its followers to monitor OTC Markets filings tab for further newsworthy events and corporate updates, which will follow as they happen (http://www.ppjenterprise.com).
FI$HING FOR THE NEXT TROPHY
$UPERMAN OPINIONS MAY CHANGE WITHOUT NOTICE
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM